Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.

Brennan DJ, Brändstedt J, Rexhepaj E, Foley M, Pontén F, Uhlén M, Gallagher WM, O'Connor DP, O'Herlihy C, Jirstrom K.

BMC Cancer. 2010 Apr 1;10:125. doi: 10.1186/1471-2407-10-125.

2.

Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.

Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K.

Breast Cancer Res. 2008;10(5):R79. doi: 10.1186/bcr2146. Epub 2008 Sep 22.

3.

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.

Brennan DJ, Laursen H, O'Connor DP, Borgquist S, Uhlen M, Gallagher WM, Pontén F, Millikan RC, Rydén L, Jirström K.

Breast Cancer Res. 2011 Jan 31;13(1):R12. doi: 10.1186/bcr2820.

4.

HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.

Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirström K.

Int J Cancer. 2008 Sep 1;123(5):1146-53. doi: 10.1002/ijc.23597.

5.

HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.

Bengtsson E, Nerjovaj P, Wangefjord S, Nodin B, Eberhard J, Uhlén M, Borgquist S, Jirström K.

Diagn Pathol. 2014 Apr 7;9:78. doi: 10.1186/1746-1596-9-78.

6.

The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.

Butt S, Butt T, Jirström K, Hartman L, Amini RM, Zhou W, Wärnberg F, Borgquist S.

Ann Surg Oncol. 2014 Sep;21(9):2911-9. doi: 10.1245/s10434-014-3708-4. Epub 2014 Apr 29.

PMID:
24777857
7.

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.

Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström K.

J Transl Med. 2011 Jul 21;9:114. doi: 10.1186/1479-5876-9-114.

8.

Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer.

Berntsson J, Lundgren S, Nodin B, Uhlén M, Gaber A, Jirström K.

J Ovarian Res. 2014 Feb 26;7:26. doi: 10.1186/1757-2215-7-26.

10.

HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.

Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Sundara-Rajan S, Humphries MP, Barba M, Speirs V, De Maria R, Maugeri-Saccà M.

Sci Rep. 2016 Oct 7;6:35121. doi: 10.1038/srep35121.

11.

Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas.

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS.

Ann Oncol. 2004 Oct;15(10):1535-42.

PMID:
15367415
12.

Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM.

BMC Cancer. 2010 Nov 23;10:639. doi: 10.1186/1471-2407-10-639.

13.

Impact of statin therapy on survival in epithelial ovarian cancer.

Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ.

Gynecol Oncol. 2008 Oct;111(1):102-5.

PMID:
20698078
14.

Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.

Beussel S, Hasenburg A, Bogatyreva L, Hauschke D, Werner M, Lassmann S.

J Clin Pathol. 2012 Jan;65(1):29-35. doi: 10.1136/jclinpath-2011-200212. Epub 2011 Oct 19.

PMID:
22011448
15.

The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer.

Brennan DJ, Ek S, Doyle E, Drew T, Foley M, Flannelly G, O'Connor DP, Gallagher WM, Kilpinen S, Kallioniemi OP, Jirstrom K, O'Herlihy C, Borrebaeck CA.

Eur J Cancer. 2009 May;45(8):1510-7. doi: 10.1016/j.ejca.2009.01.028. Epub 2009 Mar 9.

PMID:
19272768
16.
17.

Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.

Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC; Gynecologic Oncology Group.

Cancer. 2008 May 15;112(10):2202-10. doi: 10.1002/cncr.23390.

18.

Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.

Eltze E, Wild PJ, Wülfing C, Zwarthoff EC, Burger M, Stoehr R, Korsching E, Hartmann A.

Eur Urol. 2009 Nov;56(5):837-45. doi: 10.1016/j.eururo.2008.10.003. Epub 2008 Oct 11.

PMID:
18945538
19.

Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.

Messa C, Notarnicola M, Russo F, Cavallini A, Pallottini V, Trentalance A, Bifulco M, Laezza C, Gabriella Caruso M.

Scand J Gastroenterol. 2005 Dec;40(12):1454-61.

PMID:
16293557
20.

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff BJ, Kalloger SE, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia JJ, Schoolmeester JK, Bakkum-Gamez J, Tinker AV, Bowtell DD, Huntsman DG, Gilks CB, McAlpine JN.

J Pathol. 2013 Jan;229(1):111-20. doi: 10.1002/path.4088.

PMID:
22899400

Supplemental Content

Support Center